China · Delayed Price · Currency is CNY Mabwell (Shanghai) Bioscience Company Description
Mabwell (Shanghai) Bioscience Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacture, and commercialization of biological products for oncology, immunology, bone disorders, ophthalmology, hematology, and infectious diseases in China and internationally.
The company offers MAIWEIJIAN for the treatment of giant cell tumor of bone; MALISHU for the treatment of postmenopausal women with osteoporosis; and JUNMAIKANG, an autoimmune Adalimumab injection.
Its oncology product pipeline includes 9MW2821, a Nectin-4 targeting drug candidate in the Phase III clinical trials for the treatment of cervical cancer; 7MW3711, a B7-H3 targeting ADC for the treatment of advanced malignant solid tumors; and 7MW4911, an ADC that targets CDH17.
The company’s immunology product pipeline comprises 9MW1911, an anti-ST2 antibody that is in Phase I clinical trial for the treatment of COPD, and 9MW3811, an anti-IL-11 antibody that is in Phase I clinical trial.
Its bone disorder product pipeline consists of 1MW5011, an oral tablet for the treatment of osteoarthritis.
The company’s ophthalmology product pipeline includes 9MW0813, a recombinant VEGF receptor-antibody fusion protein for the treatment of ocular diseases related to vascularization; 9MW0211, a recombinant anti-VEGF humanized monoclonal antibody injection that is in Phase III clinical trials for the treatment of neovascularization-related eye diseases, such as neovascular age-related macular degeneration.
Its hematology product pipeline comprises 9MW3011, a recombinant humanized anti-TMPRSS6 monoclonal antibody that is in Phase I clinical trials for the treatment of polycythemia vera and iron overload disorders, including beta-thalassemia.
The company was founded in 2017 and is headquartered in Shanghai, China.
| Country | China |
| Founded | 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1,416 |
| CEO | Datao Liu |
Contact Details
Address: Building 2 Shanghai, 201210 China | |
| Phone | 86 21 5833 2260 |
| Website | mabwell.com |
Stock Details
| Ticker Symbol | 688062 |
| Exchange | Shanghai Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | CNE100005RD2 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Datao Liu Ph.D. | Chairman, Chief Executive Officer and GM |
| Jun Hua | Vice President, Chief Financial Officer and Deputy GM |
| Dr. Xin Du Ph.D. | Chief Scientific Officer and President of Maiwei (US) |
| Dr. Yinhan Guo Ph.D. | Chief Development Officer |
| Shu Hai Wang Ph.D. | Senior Vice President and CMO |
| Jinchao Zhang | Deputy General Manager |
| Dr. Hai Wu Ph.D. | Deputy GM, President of Research & Development and Director |
| Dr. Xun Gui | Vice President, Deputy GM and Director |
| Huiguo Hu | Senior Vice President, CCO, Secretary of the Board and Director |
| Xi Chen | Deputy General Manager |